TP53 and esophageal cancer: In an in vitro approach (Itoshima et al., 2000), esophageal cancer cells were transfected with a plasmid designed to rise ARF expression (exogenous), with the subsequent reduction of endogenous levels of Mdm2 and induced p53 accumulation.